Roche Holding AG

LSE:0QOK Stock Report

Market Cap: CHF 204.1b

Roche Holding Valuation

Is 0QOK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QOK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QOK (CHF251.35) is trading below our estimate of fair value (CHF726.3)

Significantly Below Fair Value: 0QOK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QOK?

Key metric: As 0QOK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QOK. This is calculated by dividing 0QOK's market cap by their current earnings.
What is 0QOK's PE Ratio?
PE Ratio18.9x
EarningsCHF 10.62b
Market CapCHF 204.09b

Price to Earnings Ratio vs Peers

How does 0QOK's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QOK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
AZN AstraZeneca
31.5x18.4%UK£162.4b
GSK GSK
21.7x21.9%UK£54.9b
HIK Hikma Pharmaceuticals
19.2x12.7%UK£4.4b
NOVN Novartis
17.6x7.0%CHF 183.8b
0QOK Roche Holding
18.9x11.1%CHF 204.1b

Price-To-Earnings vs Peers: 0QOK is good value based on its Price-To-Earnings Ratio (18.9x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does 0QOK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QOK 18.9xIndustry Avg. 20.1xNo. of Companies12PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QOK is good value based on its Price-To-Earnings Ratio (18.9x) compared to the European Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is 0QOK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QOK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ratio36.8x

Price-To-Earnings vs Fair Ratio: 0QOK is good value based on its Price-To-Earnings Ratio (18.9x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QOK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 251.35
CHF 303.88
+20.9%
17.1%CHF 440.00CHF 220.00n/a17
Nov ’25CHF 271.70
CHF 303.76
+11.8%
17.0%CHF 438.00CHF 220.00n/a17
Oct ’25CHF 269.92
CHF 302.00
+11.9%
17.3%CHF 440.00CHF 220.00n/a18
Sep ’25CHF 286.28
CHF 295.63
+3.3%
17.1%CHF 440.00CHF 220.00n/a19
Aug ’25CHF 285.80
CHF 287.74
+0.7%
17.1%CHF 440.00CHF 220.00n/a19
Jul ’25CHF 249.63
CHF 278.58
+11.6%
20.4%CHF 428.00CHF 210.00n/a19
Jun ’25CHF 231.00
CHF 277.53
+20.1%
20.5%CHF 428.00CHF 210.00n/a19
May ’25CHF 220.60
CHF 279.83
+26.9%
20.6%CHF 428.00CHF 210.00n/a18
Apr ’25CHF 229.73
CHF 281.28
+22.4%
19.9%CHF 424.00CHF 210.00n/a18
Mar ’25CHF 234.40
CHF 282.94
+20.7%
19.3%CHF 424.00CHF 210.00n/a18
Feb ’25CHF 237.02
CHF 298.00
+25.7%
19.5%CHF 450.00CHF 225.00n/a18
Jan ’25CHF 244.50
CHF 307.11
+25.6%
19.6%CHF 472.00CHF 225.00n/a19
Dec ’24CHF 239.35
CHF 307.83
+28.6%
18.7%CHF 472.00CHF 225.00n/a18
Nov ’24CHF 235.90
CHF 307.83
+30.5%
18.7%CHF 472.00CHF 225.00CHF 271.7018
Oct ’24CHF 250.57
CHF 313.44
+25.1%
17.2%CHF 478.00CHF 250.00CHF 269.9218
Sep ’24CHF 259.45
CHF 321.12
+23.8%
16.6%CHF 477.27CHF 250.00CHF 286.2819
Aug ’24CHF 270.07
CHF 326.77
+21.0%
16.1%CHF 477.48CHF 250.00CHF 285.8020
Jul ’24CHF 274.35
CHF 328.02
+19.6%
16.0%CHF 456.47CHF 250.00CHF 249.6319
Jun ’24CHF 289.39
CHF 333.63
+15.3%
15.9%CHF 456.47CHF 250.00CHF 231.0021
May ’24CHF 277.98
CHF 335.49
+20.7%
15.3%CHF 450.00CHF 250.00CHF 220.6022
Apr ’24CHF 260.99
CHF 344.08
+31.8%
15.3%CHF 450.00CHF 250.00CHF 229.7323
Mar ’24CHF 272.38
CHF 349.87
+28.5%
13.9%CHF 450.00CHF 250.00CHF 234.4024
Feb ’24CHF 281.24
CHF 354.91
+26.2%
13.3%CHF 465.00CHF 265.00CHF 237.0224
Jan ’24CHF 291.77
CHF 371.08
+27.2%
11.0%CHF 450.00CHF 300.00CHF 244.5024
Dec ’23CHF 310.00
CHF 373.83
+20.6%
10.6%CHF 450.00CHF 300.00CHF 239.3524
Nov ’23CHF 329.50
CHF 375.29
+13.9%
10.5%CHF 450.00CHF 300.00CHF 235.9024

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.75

7D

0.4%

1Y

-5.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

2.4%

1Y

12.5%